Loading
Latest filing published 07 Aug 2026 for OKYO Pharma Ltd, €4,292. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Gary S. Jacob, listed as chief executive, appears in our data through filings on OKYO Pharma Ltd shares, published by SEC (Form 4). We count 3 filings; the first trade dates from 19 May 2022 and the latest from 21 July 2026.
Every open-market trade on record is a purchase: 2 purchases worth €52k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant. In 2026 alone, the filings show 1 purchase and no sales.
The latest filing, published on 7 August 2026, reports an open-market purchase of €4,292 in OKYO Pharma Ltd. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations